SVF
Level D· Preclinical EvidenceLaboratory Study

Enhancing Lumbar Spinal Fusion Using Hypoxia Preconditioned Culture-Expanded Adipose-Derived Mesenchymal Stem Cells: Evidence From a Rat Posterolateral Lumbar Spinal Fusion Model.

Perdomo-Pantoja A., Shafi M., Sarkar N., Rajkovic C., Holmes C., Cottrill E.

Laboratory Study on Back & Spine, published in Neurosurgery (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Neurosurgery (2026)
Country
United States
Reported sample size
—
PMID
42017849
DOI
10.1227/neu.0000000000004055

Abstract (original English)

Adipose-derived stem cells (ADSCs) offer a practical alternative to bone marrow-derived stem cells. They are often limited by poor cell survival following implantation into the hypoxic environment surrounding the fusion site. Dimethyloxalylglycine (DMOG), a stabilizer of hypoxia-inducible factor-1α, has been shown to boost both osteogenic and angiogenic functions of mesenchymal stem cells under low oxygen conditions. In this study, we investigated whether preconditioning ADSCs with DMOG and hypoxia could improve their bone-forming capacity and stimulate vascularization. ADSCs were harvested from the inguinal fat pads of Lewis rats aged 6-8 weeks. After culture expansion, cells at passage 1 (P1) (80% confluency) were preconditioned with DMOG (1 ng) for 24 hours. Cells at passage 2 (P2) were then seeded onto Vitoss scaffolds at a dose of 2 × 106 cells per scaffold for implantation. Rats underwent L4-L5 posterolateral spinal fusion and were randomly assigned to 1 of 2 groups: (1) Vitoss containing DMOG-preconditioned P2 ADSCs or (2) Vitoss containing nonpreconditioned P2 ADSCs. Fusion outcomes were evaluated 8 weeks postoperatively using manual palpation (graded as 0 = nonfused, 1 = partial fusion, and, 2 = fused), micro-computed tomography (micro-CT) imaging (0 = nonfused; 1 = unilateral fusion; 2 = bilateral fusion), and histology. Micro-CT demonstrated that rats receiving DMOG-

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Back & Spine
View on PubMedDOI

Related research